98%
921
2 minutes
20
Microtubules and nuclear transmembrane SUN1/2 proteins promote the mobility of DNA Double Strand Breaks (DSBs) induced by ionizing radiation and the misrepair of one-ended DSBs induced in BRCA1-deficient cells by Poly(ADP-ribose) polymerase inhibitors (PARPi). However, whether microtubules promote aberrant DSBs repair by altering the nuclear structure and whether the nuclear structure itself plays a role in these processes is still unclear. Here we show that microtubule-dependent DSBs mobility in BRCA1-deficient cells after PARPi treatment is associated with nuclear envelope (NE) invaginations. Furthermore, increasing NE invaginations by Lmna deletion or inhibition of sphingolipid synthesis increases DSBs mobility, chromosomal aberrations, and PARPi cytotoxicity in BRCA1-deficient cells. These findings reveal a functional connection between the NE and DSB repair and suggest that drugs increasing NE deformability will enhance PARPi therapy efficacy in BRCA1-deficient cancers.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174318 | PMC |
http://dx.doi.org/10.1038/s41467-025-60756-8 | DOI Listing |
Nucleic Acids Res
July 2025
Key Laboratory of Laparoscopic Technology of Zhejiang Province, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, 310016 Hangzhou, P. R. China.
Microhomology-mediated tandem duplication (TD) is a distinct mutational signature in BRCA1-deficient tumors. While several mechanisms have been proposed for its generation, much understanding comes from repeat-based reporters, which may not represent the region of the human genome lacking neighboring repeats. To address this limitation, we developed a repeat-less TD reporter and a PCR-based endogenous site-specific TD assay to examine TDs induced by replication-coupled single-ended DNA double-strand breaks (seDSBs) in Brca1-deficient mouse embryonic stem cells.
View Article and Find Full Text PDFHear Res
September 2025
International Cancer Center, Marshall Laboratory of Biomedical Engineering, Department of Otolaryngology, The First Affiliated Hospital, Department of Anatomy and Histology, Shenzhen University Medical School, Shenzhen 518060, China. Electronic address:
Platinum-based chemotherapy drugs, including cisplatin (CDDP), are known to cause irreversible hearing loss. We recently discovered that BRCA1 facilitates the repair of CDDP-induced DNA double-strand breaks (DSBs) in cochlear hair cells (HCs) and prevents hearing loss. However, the checkpoint pathways activated in response to DSBs in HCs, and the mechanisms by which Brca1 regulates these pathways, remain unclear.
View Article and Find Full Text PDFJ Med Chem
July 2025
Department of Chemical Biology and Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
Ovarian cancer (OC) is a lethal gynecologic malignancy with limited treatments. Platinum(II) drugs are commonly used but faced severe toxicities and resistance. This study developed theophylline-platinum(IV) prodrugs (-) to combat BRCA1-deficient OC via synthetic lethality strategy.
View Article and Find Full Text PDFDNA Repair (Amst)
August 2025
Facultad de Biología, Universidad de Sevilla, Sevilla 41080, Spain; Centro Andaluz de Biología Molecular y Medicina Regenerativa-CABIMER, Universidad de Sevilla-CSIC-Universidad Pablo de Olavide, Sevilla 41092, Spain. Electronic address:
DNA end resection is a critical step that governs how a broken chromosome will be repaired. As such, it is heavily regulated by multiple cellular signals and processes. Alterations in the regulation of DNA end resection have consequences for cell survival upon exposure to cytotoxic agents, including those used during cancer chemotherapy.
View Article and Find Full Text PDFNucleic Acids Res
June 2025
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Poly(ADP-ribose) polymerase inhibitors (PARPi) have greatly improved survival of cancer patients harboring BRCA1 mutations. However, therapy resistance develops via either restoration of homologous recombination or replication fork stabilization. Therapeutic targets to overcome PARPi resistance are critically needed.
View Article and Find Full Text PDF